TENAFLY, N.J., Sept. 12 /PRNewswire/ -- Rosetta Genomics Ltd., a privately
held biopharmaceutical company that develops microRNA-based therapeutic and
diagnostic agents, and Ambion, Inc., an Austin, TX-based life sciences company
that develops technologies for RNA analysis, today announced a collaborative
licensing agreement that will provide Ambion access to proprietary microRNA
(miRNA) sequences discovered and owned by Rosetta Genomics. The agreement
enables Ambion to adapt its microRNA platforms to detect, quantify, and
functionally characterize Rosetta Genomics' proprietary microRNA sequences.
The resulting products will facilitate basic and applied microRNA research
initiatives by academic and industrial scientists worldwide.
"Identifying and understanding the role of microRNAs in human health
represents a new frontier in therapeutic and diagnostic research. We are very
pleased that this agreement with Rosetta Genomics allows us to expand our
product offering for researchers studying microRNAs, making it possible to
more thoroughly examine the roles of microRNAs in biological processes like
neural development, immune response, viral infection, and oncogenesis," said
Matt Winkler, Chief Executive Officer of Ambion.
There is a growing body of evidence that microRNAs appear in different
concentrations in healthy cells versus diseased cells. Thus, measuring and
altering the amount of microRNAs in cells could be a promising tool in
diagnosis and treatment for a range of diseases.
"MicroRNAs appear to play a critical role in gene expression and
regulation, and are, therefore, likely to play a pivotal role in both the
diagnosis and treatment of many diseases. Our collaboration with Ambion will
make it possible to apply Rosetta's technology and microRNA database to
research efforts that will have a significant impact on human health in the
years ahead," said Amir Avniel, President of Rosetta Genomics.
MicroRNA molecules are a recently discovered class of small RNA molecules
that are critical in the development and life cycle of humans, animals, and
plants. MicroRNAs are major regulators of global gene expression and likely
play significant roles in the manifestation of many disease states. Recent
evidence indicates that microRNAs play a critical role in the development of
cancer and certain viral infections.
About Rosetta Genomics
Rosetta Genomics Ltd., a private biopharmaceutical company with operations
in the United States and Israel, is a world leader in the development of
microRNA-based therapeutic and diagnostic agents. The company has developed a
large and growing database of novel microRNA genes identified via its
proprietary chip technology and computational algorithms. The company has
filed several patents related to its novel microRNAs. Rosetta's current
development endeavors include unique classes of microRNA agents with potential
applications in the diagnosis and treatment of a wide range of diseases. For
more information, please visit Rosetta Genomics at:
Ambion, Inc., The RNA Company(R), is a leader in the development and
supply of innovative, RNA-based life science research and molecular diagnostic
products. Ambion has taken a leadership role in developing products for
handling, preserving, isolating, detecting and measuring RNA in areas such as
molecular biology, cell biology, microbiology, drug discovery and genomics.
Ambion has been active in microRNA research and providing microRNA-related
products since 2002. Ambion has filed several patents related to technologies
for analyzing microRNAs as well as the identities of microRNAs related to
cancer and other human diseases. For more information, please visit Ambion
SOURCE Rosetta Genomics Ltd.; Ambion, Inc.